NASDAQ:ENSC Ensysce Biosciences (ENSC) Stock Price, News & Analysis → What is Medicare Supplement Insurance? (From Tranzact) (Ad) Free ENSC Stock Alerts $0.58 +0.04 (+7.35%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.55▼$0.6350-Day Range$0.55▼$0.9552-Week Range$0.53▼$7.20Volume176,560 shsAverage Volume92,571 shsMarket Capitalization$4.28 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Ensysce Biosciences alerts: Email Address Ensysce Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,098.2% Upside$7.00 Price TargetShort InterestHealthy0.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.03) to ($2.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.83 out of 5 stars 3.5 Analyst's Opinion Consensus RatingEnsysce Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnsysce Biosciences has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.14% of the float of Ensysce Biosciences has been sold short.Short Interest Ratio / Days to CoverEnsysce Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ensysce Biosciences has recently decreased by 76.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnsysce Biosciences does not currently pay a dividend.Dividend GrowthEnsysce Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENSC. Previous Next 1.7 News and Social Media Coverage News SentimentEnsysce Biosciences has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ensysce Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ENSC on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders52.70% of the stock of Ensysce Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.63% of the stock of Ensysce Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ensysce Biosciences are expected to grow in the coming year, from ($3.03) to ($2.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ensysce Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ensysce Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad TranzactWhat is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. Learn More Here About Ensysce Biosciences Stock (NASDAQ:ENSC)Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Read More ENSC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENSC Stock News HeadlinesApril 25, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge MagazineApril 25, 2024 | finance.yahoo.comEnsysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge MagazineApril 28, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 9, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceMarch 18, 2024 | investorplace.comENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023March 15, 2024 | finance.yahoo.comENSC Striding Toward Opioid ReplacementMarch 15, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | benzinga.comEnsysce Biosciences Stock (NASDAQ:ENSC), Short Interest ReportApril 28, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 21, 2024 | finance.yahoo.comEnsysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose ProtectionFebruary 16, 2024 | finance.yahoo.comENSC: Investors Should Pay AttentionFebruary 15, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces Publication of Clinical Bioequivalence ManuscriptFebruary 15, 2024 | finance.yahoo.comEnsysce Biosciences Announces Publication of Clinical Bioequivalence ManuscriptFebruary 13, 2024 | msn.comEnsysce Biosciences falls on exercise of warrants for $4.7M gross proceedsFebruary 13, 2024 | finance.yahoo.comEnsysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross ProceedsFebruary 6, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual ConferenceFebruary 6, 2024 | finance.yahoo.comEnsysce Biosciences Selected to Present at American Association of Pain Medicine Annual ConferenceJanuary 31, 2024 | finance.yahoo.comEnsysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe PainJanuary 25, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL MeetingJanuary 25, 2024 | finance.yahoo.comEnsysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL MeetingJanuary 23, 2024 | seekingalpha.comEnsysce rallies 22% on FDA update for overdose-resistant opioidJanuary 23, 2024 | finance.yahoo.comOpioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's WhyJanuary 23, 2024 | finance.yahoo.comENSC Announces Major FDA DesignationJanuary 23, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPARJanuary 23, 2024 | finance.yahoo.comEnsysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPARJanuary 17, 2024 | msn.comEnsysce Biosciences files to sell common stock, warrantsJanuary 8, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Issues 2024 Shareholder LetterSee More Headlines Receive ENSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2024Today4/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ENSC CUSIPN/A CIK1716947 Webensysce.com Phone858-263-4196FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+1,098.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($5.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-476.29% Pretax Margin-476.29% Return on Equity-1,024.79% Return on Assets-262.37% Debt Debt-to-Equity RatioN/A Current Ratio0.69 Quick Ratio0.69 Sales & Book Value Annual Sales$2.23 million Price / Sales1.92 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-2.78Miscellaneous Outstanding Shares7,330,000Free Float3,467,000Market Cap$4.28 million OptionableNot Optionable Beta0.77 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. D. Lynn Kirkpatrick Ph.D. (Age 67)President, CEO & Director Comp: $414.77kMr. David C. Humphrey CPA (Age 55)CFO, Secretary & Treasurer Comp: $348.15kMr. Geoffrey Birkett (Age 61)Chief Commercial Officer Comp: $322kDr. Jeffrey Millard Ph.d. (Age 48)Chief Operating Officer Dr. William K. Schmidt Ph.D. (Age 73)Chairman of Clinical Advisory Board & Chief Medical Officer Dr. Linda Pestano Ph.D. (Age 54)Chief Development Officer More ExecutivesKey CompetitorsSoligenixNASDAQ:SNGXArtelo BiosciencesNASDAQ:ARTLHillstream BioPharmaNASDAQ:HILSZyVersa TherapeuticsNASDAQ:ZVSALipella PharmaceuticalsNASDAQ:LIPOView All Competitors ENSC Stock Analysis - Frequently Asked Questions Should I buy or sell Ensysce Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ensysce Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENSC shares. View ENSC analyst ratings or view top-rated stocks. What is Ensysce Biosciences' stock price target for 2024? 1 brokers have issued 1 year price targets for Ensysce Biosciences' shares. Their ENSC share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,098.2% from the stock's current price. View analysts price targets for ENSC or view top-rated stocks among Wall Street analysts. How have ENSC shares performed in 2024? Ensysce Biosciences' stock was trading at $1.06 at the beginning of 2024. Since then, ENSC shares have decreased by 44.9% and is now trading at $0.5842. View the best growth stocks for 2024 here. Are investors shorting Ensysce Biosciences? Ensysce Biosciences saw a decrease in short interest in April. As of April 15th, there was short interest totaling 4,100 shares, a decrease of 76.6% from the March 31st total of 17,500 shares. Based on an average trading volume of 1,430,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.1% of the shares of the company are sold short. View Ensysce Biosciences' Short Interest. When is Ensysce Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ENSC earnings forecast. How were Ensysce Biosciences' earnings last quarter? Ensysce Biosciences, Inc. (NASDAQ:ENSC) issued its earnings results on Friday, March, 15th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.27. The business earned $0.52 million during the quarter, compared to analysts' expectations of $0.53 million. Ensysce Biosciences had a negative net margin of 476.29% and a negative trailing twelve-month return on equity of 1,024.79%. When did Ensysce Biosciences' stock split? Ensysce Biosciences shares reverse split on the morning of Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Ensysce Biosciences? Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENSC) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyUrgent Nvidia WarningAltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
